Tracing the Impact of Public Health Interventions on HIV-1 Transmission in Portugal Using Molecular Epidemiology.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
19 06 2019
Historique:
received: 29 11 2018
accepted: 21 02 2019
pubmed: 26 2 2019
medline: 25 2 2020
entrez: 27 2 2019
Statut: ppublish

Résumé

Estimation of temporal changes in human immunodeficiency virus (HIV) transmission patterns can help to elucidate the impact of preventive strategies and public health policies. Portuguese HIV-1 subtype B and G pol genetic sequences were appended to global reference data sets to identify country-specific transmission clades. Bayesian birth-death models were used to estimate subtype-specific effective reproductive numbers (Re). Discrete trait analysis (DTA) was used to quantify mixing among transmission groups. We identified 5 subtype B Portuguese clades (26-79 sequences) and a large monophyletic subtype G Portuguese clade (236 sequences). We estimated that major shifts in HIV-1 transmission occurred around 1999 (95% Bayesian credible interval [BCI], 1998-2000) and 2000 (95% BCI, 1998-2001) for subtypes B and G, respectively. For subtype B, Re dropped from 1.91 (95% BCI, 1.73-2.09) to 0.62 (95% BCI,.52-.72). For subtype G, Re decreased from 1.49 (95% BCI, 1.39-1.59) to 0.72 (95% BCI, .63-.8). The DTA suggests that people who inject drugs (PWID) and heterosexuals were the source of most (>80%) virus lineage transitions for subtypes G and B, respectively. The estimated declines in Re coincide with the introduction of highly active antiretroviral therapy and the scale-up of harm reduction for PWID. Inferred transmission events across transmission groups emphasize the importance of prevention efforts for bridging populations.

Sections du résumé

BACKGROUND
Estimation of temporal changes in human immunodeficiency virus (HIV) transmission patterns can help to elucidate the impact of preventive strategies and public health policies.
METHODS
Portuguese HIV-1 subtype B and G pol genetic sequences were appended to global reference data sets to identify country-specific transmission clades. Bayesian birth-death models were used to estimate subtype-specific effective reproductive numbers (Re). Discrete trait analysis (DTA) was used to quantify mixing among transmission groups.
RESULTS
We identified 5 subtype B Portuguese clades (26-79 sequences) and a large monophyletic subtype G Portuguese clade (236 sequences). We estimated that major shifts in HIV-1 transmission occurred around 1999 (95% Bayesian credible interval [BCI], 1998-2000) and 2000 (95% BCI, 1998-2001) for subtypes B and G, respectively. For subtype B, Re dropped from 1.91 (95% BCI, 1.73-2.09) to 0.62 (95% BCI,.52-.72). For subtype G, Re decreased from 1.49 (95% BCI, 1.39-1.59) to 0.72 (95% BCI, .63-.8). The DTA suggests that people who inject drugs (PWID) and heterosexuals were the source of most (>80%) virus lineage transitions for subtypes G and B, respectively.
CONCLUSIONS
The estimated declines in Re coincide with the introduction of highly active antiretroviral therapy and the scale-up of harm reduction for PWID. Inferred transmission events across transmission groups emphasize the importance of prevention efforts for bridging populations.

Identifiants

pubmed: 30805610
pii: 5364937
doi: 10.1093/infdis/jiz085
pmc: PMC6581889
doi:

Substances chimiques

pol Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-243

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204311/Z/16/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Virus Evol. 2016 Apr 27;2(1):vew010
pubmed: 27774303
Virus Evol. 2018 Jan 29;4(1):vex044
pubmed: 29403651
AIDS. 2014 Aug 24;28(13):1967-75
pubmed: 24991999
Science. 2004 Nov 26;306(5701):1561-5
pubmed: 15567864
Mol Biol Evol. 2016 Aug;33(8):2167-9
pubmed: 27189542
Retrovirology. 2017 Feb 21;14(1):15
pubmed: 28222757
Lancet HIV. 2016 May;3(5):e231-8
pubmed: 27126490
PLoS One. 2011;6(9):e24130
pubmed: 21969855
PLoS Pathog. 2018 Feb 20;14(2):e1006895
pubmed: 29462208
Infect Genet Evol. 2007 Jun;7(3):391-8
pubmed: 17360244
Mol Biol Evol. 2012 Jan;29(1):347-57
pubmed: 21890480
AIDS Res Hum Retroviruses. 2003 Jun;19(6):511-7
pubmed: 12892060
Bioinformatics. 2005 Mar 1;21(5):676-9
pubmed: 15509596
J Clin Microbiol. 2015 May;53(5):1506-14
pubmed: 25694526
BMC Public Health. 2017 Apr 11;17(1):309
pubmed: 28399843
Clin Infect Dis. 2016 Mar 1;62(5):655-663
pubmed: 26620652
BMC Infect Dis. 2010 Sep 07;10:262
pubmed: 20822507
AIDS. 1989 Dec;3(12):807-17
pubmed: 2517202
J Math Biol. 2008 Mar;56(3):391-412
pubmed: 17874105
Mol Biol Evol. 2011 May;28(5):1605-16
pubmed: 21135151
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
PLoS Med. 2015 Nov 03;12(11):e1001898; discussion e1001898
pubmed: 26529093
AIDS Rev. 2003 Jan-Mar;5(1):52-61
pubmed: 12875108
Infect Genet Evol. 2008 May;8(3):239-46
pubmed: 17921073
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
BMC Bioinformatics. 2013 Nov 06;14:317
pubmed: 24191891
J Virol. 2001 Dec;75(23):11686-99
pubmed: 11689650
PLoS One. 2017 Feb 24;12(2):e0172473
pubmed: 28234955
AIDS. 2016 Nov 28;30(18):2885-2890
pubmed: 27824626
PLoS Comput Biol. 2014 Apr 10;10(4):e1003537
pubmed: 24722319
Retrovirology. 2013 Jan 14;10:7
pubmed: 23317093
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):228-33
pubmed: 23248286
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):428-35
pubmed: 26258569
Science. 2014 Oct 3;346(6205):56-61
pubmed: 25278604
AIDS Res Hum Retroviruses. 2014 Feb;30(2):118-26
pubmed: 23947948
PLoS One. 2017 Feb 2;12(2):e0171062
pubmed: 28152089
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):313-25
pubmed: 11897032
Int J Drug Policy. 2014 Jan;25(1):34-52
pubmed: 23973009
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
PLoS Comput Biol. 2009 Sep;5(9):e1000520
pubmed: 19779555
Mol Biol Evol. 2009 Jul;26(7):1641-50
pubmed: 19377059

Auteurs

Tetyana I Vasylyeva (TI)

Department of Zoology, University of Oxford, United Kingdom.
New College, University of Oxford, United Kingdom.

Louis du Plessis (L)

Department of Zoology, University of Oxford, United Kingdom.

Andrea C Pineda-Peña (AC)

Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa.
Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia.
Basic Sciences Department, Universidad del Rosario, Bogotá, Colombia.

Denise Kühnert (D)

Max Planck Institute for the Science of Human History, Jena, Germany.

Philippe Lemey (P)

Laboratory for Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Belgium.

Anne-Mieke Vandamme (AM)

Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa.
Laboratory for Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Belgium.

Perpétua Gomes (P)

Laboratory of Molecular Biology, LMCBM, SPC, Hospital de Egas Moniz-Centro Hospitalar de Lisboa Ocidental, Lisbon.
Center for Interdisciplinary Research Egas Moniz, CiiEM, Almada, Portugal.

Ricardo J Camacho (RJ)

Laboratory for Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Belgium.

Oliver G Pybus (OG)

Department of Zoology, University of Oxford, United Kingdom.

Ana B Abecasis (AB)

Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa.

Nuno R Faria (NR)

Department of Zoology, University of Oxford, United Kingdom.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH